Perioperative Anaphylaxis: A Dynamic Challenge
Though rare, with an incidence of 1 in 2,000 to 1 in 20,000 procedures, perioperative anaphylaxis carries a significantly higher mortality rate than anaphylaxis occurring in the community. This heightened risk is driven by the unique and complex setting of surgery.
The initial sign of anaphylaxis is often not a rash, but cardiovascular collapse (severe hypotension), which is frequently mistaken for a routine anesthetic effect.
Key Triggers: Established & Emerging
Primary & Known Triggers:
- Neuromuscular blocking agents (NMBAs)
- β-lactam antibiotics
- Latex (incidence is declining with systematic avoidance)
Emerging Triggers of Concern:
- Chlorhexidine
- Patent blue dye
- Remimazolam (case reports exist; cross-reactivity with midazolam remains inconclusive)
High-Risk Groups for Latex Allergy:
- Spina bifida patients
- Those with chronic bladder catheterization
- Healthcare workers
- Patients with multiple prior surgeries
Experimental Finding:
A pilot study identified distinct circulating bacterial DNA (from Enterobacteriaceae and Veillonellaceae families) in NMBA-allergic patients. This finding correlated with tryptase and IgE levels but requires further validation.
Diagnostic Challenges & Clues
Atypical Presentation
- Cutaneous signs are rare. The classic "rash" is often absent.
- The initial sign is frequently severe hypotension, easily mistaken for anesthetic effects.
A Key Indicator: Low End-Tidal CO₂ (ETCO₂)
- The combination of hypotension with a low ETCO₂ is a critical red flag.
- The mean lowest ETCO₂ in anaphylaxis was 17 mmHg vs. 32 mmHg in other causes (AUC 0.95).
- A cutoff of ~23 mmHg is 92% sensitive and 94% specific for anaphylaxis.
- Note: This is not specific (also seen in hemorrhage or pulmonary embolism), but it is a highly valuable clue.
Bronchospasm:
- Often severe, presenting as increased airway pressure.
Laboratory Biomarkers
- Serum Tryptase: Elevated in approximately 71% of perioperative hypersensitivity reactions.
- Plasma Histamine: Has an early, short half-life. Sample immediately and within 1–2 hours (threshold ~1.5 ng/mL at 30 min).
Acute Management
Immediate Actions:
- Stop all potential triggers (antibiotics, NMBAs, latex).
- Administer 100% oxygen.
- Aggressive crystalloid fluid resuscitation.
- Epinephrine (IM/IV titrated) is first-line therapy. Large volumes are often required.
Post-Stabilization & Diagnosis
- Skin Testing (Prick/Intradermal): The cornerstone of diagnosis. Traditionally performed 4–6 weeks post-reaction.
- Drug Provocation Tests: Used for high suspicion with negative skin tests. Definitive but high risk; only performed in expert centers.
- In vitro Specific IgE: Available for latex, some NMBAs, and antibiotics.
Prevention
- Meticulous Preoperative History: This is the single most important step.
- Risk Stratification & Clear Labeling.
- Maintain Latex-Free Operating Rooms.
- Premedication (antihistamines/corticosteroids) is ineffective for preventing latex reactions.
Future Directions
- International Registries (e.g., NAP6) for real-time surveillance.
- Validate the circulating microbiome as a predictive biomarker.
- Pharmacovigilance for remimazolam and other new agents.
- Simulation-based team training to improve acute response.
Conclusion
Perioperative anaphylaxis is a dynamic, high-stakes challenge. Its masked presentation demands a high index of suspicion, guided by the hallmark signs of profound hypotension with a low ETCO₂. Acute management relies on swift administration of epinephrine and aggressive volume expansion. Long-term safety depends on systematic prevention, accurate labeling, and rigorous allergen avoidance.